<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03748134</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308A301</org_study_id>
    <nct_id>NCT03748134</nct_id>
  </id_info>
  <brief_title>Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma</brief_title>
  <acronym>ORIENT-15</acronym>
  <official_title>A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind multi-center, phase III study comparing the efficacy and&#xD;
      safety of sintilimab or placebo in combination with chemotherapy as first-line treatment in&#xD;
      subjects with unresectable, locally advanced recurrent or metastatic esophageal squamous cell&#xD;
      carcinoma.&#xD;
&#xD;
      After the interim analysis conducted by the iDMC, an open-label assignment of experimental&#xD;
      arm therapy will continue in regions outside of China, in order to further evaluate the&#xD;
      efficacy and safety of sintilimab in combination with chemotherapy in subjects representing&#xD;
      the western population with advanced esophageal squamous cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS in overall population</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 40 months.</time_frame>
    <description>To compare the overall survival of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS in PD-L1 positive population</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 40 months.</time_frame>
    <description>To compare the OS of sintilimab vs. placebo, in combination with chemotherapy, for first-line treatment in subjects with PD-L1 positive, unresectable, locally advanced, recurrent or metastatic ESCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR in overall population</measure>
    <time_frame>From date of randomization up to 28 months.</time_frame>
    <description>To compare the objective response rate between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS in overall populationsubjects in ITT population</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the progression-free survival between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR in overall population</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the disease control rate between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR in overall population</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the duration of response between the two treatment arms in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the objective response rate between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the disease control rate between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the duration of response between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS - PD-L1 positive</measure>
    <time_frame>From date of randomization up to 28 months</time_frame>
    <description>To compare the progression-free survival between the two treatment arms in PD-L1 positive subjects in ITT population</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">746</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab in combination with investigator's choice of chemotherapy&#xD;
TP regimen: Cisplatin + paclitaxel&#xD;
or&#xD;
CP regimen: Cisplatin + fluorourcil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo in combination with investigator's choice of chemotherapy&#xD;
TP regimen: Cisplatin + paclitaxel&#xD;
or&#xD;
CP regimen: Cisplatin + fluorourcil</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>For weight &lt;60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1</description>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For weight &lt;60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75mg/m^2 IV Q3W day 1</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>87.5 mg/m^2 IV Q3W day 1, day 8 for first cycle and 175mg/m^2 IV Q3W day 1 after first cycle</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>800 mg/m^2 IV continuous infusion over 24 hours daily on Days 1-5 Q3W</description>
    <arm_group_label>Placebo + chemotherapy</arm_group_label>
    <arm_group_label>Sintilimab + chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histopathologically confirmed unresectable, locally advanced, recurrent or metastatic&#xD;
             ESCC (excluding mixed adenosquamous carcinoma and other histological subtypes)&#xD;
&#xD;
          -  ECOG PS of 0 or 1&#xD;
&#xD;
          -  Subject must be unsuitable for definitive treatment, such as definitive&#xD;
             chemoradiotherapy and/or surgery. For subjects who have received (neo)adjuvant or&#xD;
             definitive chemotherapy/radiochemotherapy, time from the completion of last treatment&#xD;
             to disease recurrence must be &gt; 6 months Could provide archival or fresh tissues for&#xD;
             PD-L1 expression analysis with obtainable results&#xD;
&#xD;
          -  Have at least one measurable lesion as per RECIST v1.1&#xD;
&#xD;
        Key exclusion Criteria:&#xD;
&#xD;
          -  ESCC with endoscopy-confirmed near-complete obstruction requiring interventional&#xD;
             therapy&#xD;
&#xD;
          -  Post stent implantation in the esophagus or trachea with risk of perforation&#xD;
&#xD;
          -  Received systemic treatment for advanced or metastatic ESCC.&#xD;
&#xD;
          -  Received a cumulative dose of cisplatin ≥ 300 mg/m2 and the last cisplatin dose was&#xD;
             within 12 months of randomization or the first dose of study treatment in the&#xD;
             open-label phase.&#xD;
&#xD;
          -  High risk of hemorrhage or perforations due to tumor invasion in adjacent organs&#xD;
             (aorta or trachea), or have fistula formation.&#xD;
&#xD;
          -  Hepatic metastasis &gt; 50% of the total liver volume.&#xD;
&#xD;
          -  Received palliative therapy for a local lesion within 2 weeks prior to the first dose.&#xD;
&#xD;
          -  Received systemic treatment with Chinese traditional medicines with anti-cancer&#xD;
             indications or immunomodulators (including thymosins, interferons, and interleukins)&#xD;
             within 2 weeks prior to the first dose of study treatment.&#xD;
&#xD;
          -  Received systemic immunosuppressants within 2 weeks prior to randomization, excluding&#xD;
             local use of glucocorticoids administered by nasal, inhaled, or other routes, and&#xD;
             systemic glucocorticoids at physiological doses (no more than 10 mg/day of prednisone&#xD;
             or equivalents), or glucocorticoids to prevent allergies to contrast media.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Winnie Leung</last_name>
    <phone>+86 21 31837200</phone>
    <email>winnie.leung@innoventbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Pan</last_name>
    <phone>+86 21 31655781</phone>
    <email>xinchun.pan@innoventbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare - Virginia K. Crosson Cancer Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>949-824-5011</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers, LLP</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>719-577-2555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>IACT Health - John B. Amos Cancer center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>706-320-8700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma University Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-1112</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>512-427-9400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-404-6727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>East Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 2 6064 1515</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Queen Elizabeth Hospital</name>
      <address>
        <city>Woodville South</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+65-8-8222 6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3079</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 3 9496 5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 8 6457 3333</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St John of God Subiaco Hospital</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+61 8 9382 6111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Gent</name>
      <address>
        <city>Gent</city>
        <state>Corneel Heymanslaan 10</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 9 332 21 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Herestraat 49</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 16 33 22 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc Av.</name>
      <address>
        <city>Bruxelles</city>
        <state>Hippocrate 10</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 2 764 11 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 2 541 31 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Verviers</name>
      <address>
        <city>Verviers</city>
        <zip>4800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 87 21 21 11</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Bettancourt La Ferree</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 3 81 66 81 66</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 5 56 33 33 33</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 2 31 45 50 50</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 47 37 50750</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Faculte de Medecine</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>: +33 3 80 39 50 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oscar Lambret Centre</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 3 20 29 59 59</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 91 38 00 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 1 56 09 38 86</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 5 49 44 44 44</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles-Nicolle de Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 2 32 88 18 82</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 3 83 59 84 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Országos Onkológiai Intézet</name>
      <address>
        <city>Budapest</city>
        <state>Ráth György U. 7-9</state>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+36 1 224 8600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jósa András Oktatókórház</name>
      <address>
        <city>Nyíregyháza</city>
        <state>Szent István U. 68</state>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+36 42 599 700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 942 20 25 20</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 932 483 000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 934 893 000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 916 006 000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 972 940 200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 973 248 100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>280402</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 915 504 800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 917 27 70 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 948 255 400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Parc Taulí Sabadell Hospital Universitari</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 937 231 010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 981 950 000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 955 008 000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Hospital General Universitari de València</name>
      <address>
        <city>Valencia</city>
        <zip>46016</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 961 972 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 976 765 500</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>China</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>November 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2018</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESCC</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Esophageal Neoplasms Malignant</keyword>
  <keyword>Esophageal Squamous Cell Carcinoma</keyword>
  <keyword>Neoplasms, Squamous Cell</keyword>
  <keyword>Esophageal Diseases</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>Antineoplastic Agents</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Sintilimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

